SERUM PANELS USED FOR STUDIES

 

SERUM SUPPLIED BY VACCINE COMPONENTS

1. ALAN HAMPSON ADULTS A/NEW CALEDONIA/20/99 (H1N1)

WHO, MELBOURNE ELDERLY A/PANAMA/2007/99 (H3N2)

AUSTRALIA B/JOHANNESBURG/5/99

 

2. JOHN WOOD, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1)

NIBSC, LONDON ELDERLY A/PANAMA/2007/99 (H3N2)

ENGLAND B/GUANGDONG/120/2000

3. S. GRAVENSTEIN, M.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1)

EASTERN VIRGINIA ELDERLY A/PANAMA/2007/99 (H3N2)

MEDICAL SCHOOL B/VICTROIA/504/2000

4. TAKATO ODIGARI, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1)

NIH, TOKYO ELDERLY A/PANAMA/2007/99 (H3N2)

JAPAN B/JOHANNESBURG/5/99

 

ANTIGENS FOR SEROLOGIES

 

H1N1

 

 

A/NEW CALEDONIA/20/99 *

A/HUBEI/288/2001

A/BANGKOK/255/2001

A/HAWAII/15/2001

A/WISCONSIN/12/2001

A/BRAZIL/821/2001

A/HONG KONG/747/2001

A/FUJIAN/156/2000

A/AUCKLAND/65/2001

A/CHRISTCHURCH/4/2001

 

* = VACCINE STRAIN

HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO

INFLUENZA A (H1N1) VIRUSES

TRIAL

TEST

SITE

VIRUS STRAIN

GMT

PRE POST

%>32or40

PRE POST

% 4

FOLD

RISE

USA

ADULTS

N=24

CDC

A/NíCALEDONIA/20/99* A/BRAZIL/821/2001

A/HONG KONG/747/2001

A/AUCKLAND/65/2001

21

29

31

14

92

127

120

46

33

54

54

29

88

96

96

71

42

42

42

42

   

*IVR-116 STRAIN

         
 

CBER

A/NíCALEDONIA/20/99*

A/HUBEI/288/2001

A/BANGKOK/255/2001

A/HAWAII/15/2001

A/WISCONSIN/12/2001

20

24

20

<10

11

59

78

48

22

31

42

33

33

25

25

75

75

71

58

63

42

54

42

42

42

   

*IVR-116 STRAIN

       

HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO INFLUENZA

A (H1N1) VIRUSES

TRIAL

TEST

SITE

VIRUS STRAIN

GMT

PRE POST

%>32or40

PRE POST

% 4

FOLD

RISE

AUS

ELDERLY

N=24

CDC

A/NíCALEDONIA/20/99*

A/HUBEI/288/2001

A/BANGKOK/255/2001

A/ WISCONSIN/12/2001

A/HAWAII/15/2001

8

9

7

9

7

44

41

26

40

23

8

8

4

13

4

70

65

43

61

48

63

71

63

71

50

   

* IVR-116 STRAIN

         

CBER

A/NíCALEDONIA/20/99*

A/HUBEI/288/2001

A/BANGKOK/255/2001

A/ WISCONSIN/12/2001

A/HAWAII/15/2001

10

12

<10

15

10

52

65

53

53

36

21

29

17

38

8

75

83

83

75

67

72

76

84

56

63

   

* IVR-116 STRAIN

         

 

 

 

ANTIGENS FOR SEROLOGIES

 

H3N2

 

 

 

A/PANAMA/2007/99 *

A/ARGENTINA/3759/2001

A/PHILIPPINES/78890/2001

A/SINGAPORE/26/2001

A/SINGAPORE/15/2001

A/SOUTH AUSTRALIA/102/2001

A/CHILE/6416/2001

A/HONG KONG/762/2001

A/HAWAII/21/2001

A/ALASKA/14/2001

A/DARWIN/3/2000

A/FUJIAN/140/2000

 

 

 

 

* = VACCINE STRAIN

 

 

 

HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO

INFLUENZA A (H3N2) VIRUSES

TRIAL

TEST

SITE

VIRUS STRAIN

GMT

PRE POST

>32or40

PRE POST

% 4

FOLD

RISE

EUROPE

ADULTS

N=24

CDC

A/PANAMA/2007/99*

AHONG KONG/762/2001

A/CHILE/6416/2001

A/HAWAII/21/2001

A/SINGAPORE/15/2001

9

12

7

12

6

165

120

58

261

39

13

13

4

21

0

100

100

79

100

71

100

96

96

96

88

   

* RESVIR 17 STRAIN

         

 

 

CBER

A/PANAMA/2007/99*

A/SINGAPORE/26/2001

A/DARWIN/3/2000

A/FUJIAN/140/2000

A/CHILE/6416/2001

<10 <10

<10

<10 <10

101

62

22

53

39

0

0

4

4

0

88

88

50

67

63

92

92

54

83

79

   

* RESVIR 17 STRAIN

         


HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO

INFLUENZA A (H3N2) VIRUSES

TRIAL

TEST

SITE

VIRUS STRAIN

GMT

PRE POST

%>32or40

PRE POST

% 4

FOLD

RISE

USA

ELDERLY

N=24

CDC

A/PANAMA/2007/99*

A/S AUSTRALIA/102/2001

A/PHILIPPINES/78890/01

A/ALASKA/2001

A/ARGENTINA/3759/2001

12

12

22

36

10

24

21

41

67

19

17

13

33

58

17

42

33

67

92

33

17

13

13

25

21

   

* RESVIR 17 STRAIN

         

CBER

A/PANAMA/2007/99*

A/PHILIPPINES/78890/01

A/ARGENTINA/3759/01

13

13

14

39

19

68

29

46

29

71

43

88

46

33

58

   

* RESVIR 17 STRAIN

         

 

ANTIGENS FOR SEROLOGIES

 

B

 

B/JOHANNESBURG/5/99 * **

B/GUANGDONG/120/2000 * **

B/VICTORIA/504/2000 * **

B/SICHUAN/379/99 **

B/SHIZUOKA/15/2001**

B/TEXAS/22/2001**

B/HONG KONG/692/2001 **

B/SICHUAN/317/2001 **

B/WUHAN/02/2001 **

B/SINGAPORE/1/2001 **

B/BRAZIL/952/2001 **

B/SHIZUOKA/480/2000 **

B/BRAZIL/956/2000 **

B/JOHANNESBURG/69/2001 **

B/HAWAII/10/2001 ** !

B/HONG KONG/330/2001** !

 

 

* = VACCINE STRAIN

** = ETHER TREATED

! = B/BEIJING/243/97-LIKE

HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO

INFLUENZA B VIRUSES

TRIAL

TEST

SITE

VIRUS STRAIN

GMT

PRE POST

%>32or40

PRE POST

% 4

FOLD

RISE

USA

ADULTS

N=24

CDC

B/VICTORIA/504/2000

B/SICHUAN/317/2001

B/TEXAS/22/2001

B/HONG KONG/692/01

B/JOíBURG/69/2001

44

36

34

32

18

143

110

110

104

52

71

63

54

50

25

92

92

88

92

71

38

38

38

38

33

               

CBER

B/VICTORIA/504/2000

B/SHIZUOKA/15/2001

B/TEXAS/22/2001

B/HONG/KONG/692/01

B/SICHUAN/317/2001

B/HONG KONG/330/01

60

32

32

29

23

11

176

99

93

78

58

38

67

54

54

54

50

29

88

79

79

79

79

38

42

42

46

42

29

8

               

HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO

INFLUENZA B VIRUSES

TRIAL

TEST

SITE

VIRUS STRAIN

GMT

PRE POST

%>32or40

PRE POST

% 4

FOLD

RISE

AUS

ELDERLY

N=24

AUS

B/VICTORIA/504/2000

B/BRAZIL/956/2001

B/WUHAN/02/2001

B/SHIZUOKA/15/2001

B/HONG KONG/330/01

B/HAWAII/10/2001

15

24

12

23

10

10

95

143

67

138

24

22

25

38

21

29

17

13

88

92

79

92

54

54

71

63

67

58

42

38

               

CBER

B/GUANGDONG/120/00

B/SHIZUOKA/15/2001

B/TEXAS/22/2001

B/HONG KONG/692/01

B/SICHUAN/317/2001

B/HONG KONG/330/01

12

10

<10

<10

<10

<10

100

116

76

71

71

<10

21

21

21

13

17

17

75

79

79

71

71

17

68

76

71

68

64

8

               

 

 

A/NEW CALEDONIA/20/99 VACCINES

 

 

 

H1N1 VIRUSES

VIRUSES WITH > 50% REDUCTION IN

POST-VACCINE GMT

NUMBER LOW/NUMBER TESTED

 

PER CENT REDUCTION

MEAN (RANGE)

   

CBER

CDC

   

TOTAL

 

A/HAWAII/15/2001

 

5/6

2/4

   

7/10

60 (31-82)

A/WISCONSIN/12/2001

 

1/6

0/4

   

1/10

22 (0-70)

A/HUBEI/288/2001

 

0/6

0/4

   

0/10

6 (0-27)

A/BANGKOK/255/2001

 

0/6

0/4

   

0/10

30 (0-45)

A/AUCKLAND/65/2001

 

1/3

4/6

   

5/9

46 (0-93)

A/BRAZIL/821/2001

 

ND

0/6

   

0/6

0 (0)

A/CHRISTCHURCH/4/2001

 

0/3

ND

   

0/3

6 (0-17)

ND= NO DATA

             

 

 

A/PANAMA/2007 VACCINES

 

 

 

H3N2 VIRUSES

VIRUSES WITH > 50% REDUCTION IN

POST-VACCINE GMT

NUMBER LOW/NUMBER TESTED

 

PER CENT REDUCTION

MEAN (RANGE)

   

CBER

CDC

   

TOTAL

 

A/CHILE/6416/2001

 

4/4

3/6

   

7/10

48 (0-76)

A/ARGETNTINA/3759/2001

 

0/6

0/8

   

0/14

19 (0-38)

A/PHILIPPINES/78890/2001

 

5/6

0/6

   

5/12

31 (0-76)

A/HAWAII/21/2001

 

ND

0/6

   

0/6

0 (0)

A/SINGAPORE/15/2001

 

ND

6/6

   

6/6

71 (64-76)

A/ SINGAPORE/26/2001

 

0/4

ND

   

0/4

34 (22-41)

A/S AUSTRALIA/102/2001

 

ND

2/8

   

2/8

35 (17-59)

ND= NO DATA

             

 

 

B/SICHUAN/379/99-LIKE VACCINES

 

 

 

B VIRUSES

VIRUSES WITH > 50% REDUCTION IN

POST-VACCINE GMT

NUMBER LOW/NUMBER TESTED

 

PER CENT REDUCTION

 

   

CBER

CDC

   

TOTAL

MEAN (RANGE)

B/TEXAS/22/2001

 

0/6

1/8

   

1/14

21 (0-77)

B/HONG KONG/692/2001

 

1/6

0/8

   

1/14

22 (0-56)

B/SHIZUOKA/15/2001

 

0/6

0/4

   

0/10

8 (0-44)

B/SICHUAN/317/2001

 

1/6

0/8

   

1/14

25 (0-67)

B/HAWAII/10/2001

 

4/4

4/4

   

8/8

62 (50-94)

B/HONG KONG/330/2001

 

6/6

4/4

   

10/10

74 (58-96)

               

ND= NO DATA

ETHER TREATED ANTIGEN